Drug Profile
Nimotuzumab - InnoMab
Alternative Names: BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIXLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology; CIMYM
- Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
- Phase III Cervical cancer; Non-small cell lung cancer; Pancreatic cancer
- Phase II/III Triple negative breast cancer
- Phase II Colorectal cancer
- No development reported Breast cancer; Gastric cancer; Polycystic kidney disease; Prostate cancer
- Discontinued Brain metastases; Squamous cell cancer
Most Recent Events
- 02 Apr 2024 Biotech Pharmaceutical plans a phase III trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (IV, Injection) (NCT06343116)
- 27 Mar 2024 Biotech Pharmaceutical plans a phase III trial for Cervical cancer (Late-stage disease, Combination therapy) in unknown location (IV) (NCT06333821)
- 03 Aug 2023 Biotech Pharmaceutical plans a phase III NOTABLE-307 trial in Gastric cancer (Recurrent, Second-line therapy or greater, Metastatic disease, Combination therapy) in September 2023 (IV) (NCT05978050)